Opticin Therapeutics

April 2017 - Opticin Therapeutics to Present at BioTrinity 2017, Europe’s leading Biopartnering and Investment Conference, to be held on 8-10 May at the Novotel  London West

Jun 2016 - Opticin Therapeutics is shortlisted as a finalist in the Royal Society of Chemistry's Emerging Technologies competition 

Dec 2015 - Opticin Therapeutics appoints Dr Jim Millen to lead its commercialisation and funding efforts.  Dr Millen joins with 15+ years big pharma and biotech experience 

July 2015 - CSO, Professor Paul Bishop and colleagues win prestigeous MRC DPFS grant, funding initial work towards development of Opticin as a therapeutic for human proliferative eye diseaseType your paragraph here.